These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 9050781)
21. Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia. Lee WP; Datta BN; Ong BB; Rees A; Halcox J Am J Cardiovasc Drugs; 2011 Dec; 11(6):363-70. PubMed ID: 22149315 [TBL] [Abstract][Full Text] [Related]
23. [Extracorporeal elimination of LDL-cholesterol in the treatment of hypercholesterolemia: indications and methods]. Bláha V; Havel E; Zadák Z; Pidrman V; Bláha M; Kalinová M Vnitr Lek; 1995 Oct; 41(10):724-9. PubMed ID: 8578708 [TBL] [Abstract][Full Text] [Related]
24. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). Matsuzaki M; Hiramori K; Imaizumi T; Kitabatake A; Hishida H; Nomura M; Fujii T; Sakuma I; Fukami K; Honda T; Ogawa H; Yamagishi M J Am Coll Cardiol; 2002 Jul; 40(2):220-7. PubMed ID: 12106923 [TBL] [Abstract][Full Text] [Related]
25. Up-regulation of LDL-receptor expression by LDL-immunoapheresis in patients with familial hypercholesterolemia. Streicher J; Valent P; Schmidt H; Sengölge G; Wagner O; Strobl W; Hörl WH; Derfler K J Investig Med; 1999 Sep; 47(8):378-87. PubMed ID: 10510590 [TBL] [Abstract][Full Text] [Related]
26. Impaired radial artery compliance in normotensive subjects with familial hypercholesterolemia. Giannattasio C; Mangoni AA; Failla M; Carugo S; Stella ML; Stefanoni P; Grassi G; Vergani C; Mancia G Atherosclerosis; 1996 Aug; 124(2):249-60. PubMed ID: 8830937 [TBL] [Abstract][Full Text] [Related]
27. [Clinical long-term results of H.E.L.P.-apheresis]. Schuff-Werner P Z Kardiol; 2003; 92(Suppl 3):III28-9. PubMed ID: 14663598 [TBL] [Abstract][Full Text] [Related]
28. LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia. Thiery J; Seidel D Transfus Sci; 1993 Jul; 14(3):249-59. PubMed ID: 10146336 [TBL] [Abstract][Full Text] [Related]
29. Correlation of cold pressor and flow-mediated brachial artery diameter responses with the presence of coronary artery disease. Corretti MC; Plotnick GD; Vogel RA Am J Cardiol; 1995 Apr; 75(12):783-7. PubMed ID: 7717279 [TBL] [Abstract][Full Text] [Related]
30. LDL-apheresis: results of longterm treatment and vascular outcome. Keller C Atherosclerosis; 1991 Jan; 86(1):1-8. PubMed ID: 2064631 [TBL] [Abstract][Full Text] [Related]
31. Dyslipidemia evaluated by brachial artery vasoactivity: a case study of eight patients. Rashid MN; Touchon RC W V Med J; 1999; 95(4):175-9. PubMed ID: 10466013 [TBL] [Abstract][Full Text] [Related]
32. In vivo rheologic effects of lipid apheresis techniques: comparison of dextran sulfate LDL adsorption and heparin induced LDL precipitation. Grützmacher P; Landgraf H; Esser R; Okon J; Vlachojannis J; Ehrly AM; Schoeppe W ASAIO Trans; 1990; 36(3):M327-30. PubMed ID: 2252691 [TBL] [Abstract][Full Text] [Related]
34. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group. Gordon BR; Kelsey SF; Bilheimer DW; Brown DC; Dau PC; Gotto AM; Illingworth DR; Jones PH; Leitman SF; Prihoda JS Am J Cardiol; 1992 Oct; 70(11):1010-6. PubMed ID: 1414897 [TBL] [Abstract][Full Text] [Related]
36. [The plasma antioxidant status and trace elements in patients with familial hypercholesterolemia treated with LDL-apheresis]. Delattre J; Lepage S; Jaudon MC; Bruckert E; Assogba U; Bonnefont-Rousselot D Ann Pharm Fr; 1998; 56(1):18-25. PubMed ID: 9770031 [TBL] [Abstract][Full Text] [Related]
37. Apheresis technologies for prevention and regression of atherosclerosis: clinical results. Bambauer R; Schneidewind JM; Latza R ASAIO J; 1999; 45(5):403-7. PubMed ID: 10503615 [TBL] [Abstract][Full Text] [Related]
38. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Blaha M; Cermanova M; Blaha V; Jarolim P; Andrys C; Blazek M; Maly J; Smolej L; Zajic J; Masin V; Zimova R; Rehacek V Atherosclerosis; 2008 Mar; 197(1):264-70. PubMed ID: 17540382 [TBL] [Abstract][Full Text] [Related]
39. Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein B genes. Huijgen R; Vissers MN; Kindt I; Trip MD; de Groot E; Kastelein JJ; Hutten BA Circ Cardiovasc Genet; 2011 Aug; 4(4):413-7. PubMed ID: 21642693 [TBL] [Abstract][Full Text] [Related]
40. Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia. Mattina A; Rosenbaum D; Bittar R; Bonnefont-Rousselot D; Noto D; Averna M; Bruckert E; Giral P Nutr Metab Cardiovasc Dis; 2018 May; 28(5):517-523. PubMed ID: 29525223 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]